Research programme: monoclonal antibody therapeutics - Chiome Bioscience

Drug Profile

Research programme: monoclonal antibody therapeutics - Chiome Bioscience

Alternative Names: LIV-1205; LIV-2008; LIV-2008b

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chiome Bioscience; LivTech
  • Developer ADC Therapeutics; Chiome Bioscience
  • Class Drug conjugates; Monoclonal antibodies
  • Mechanism of Action DLK-1-protein-modulators; Semaphorin modulators; TROP2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 05 Oct 2017 Chiome Bioscience signs a service and license agreement with ProBioGen for GlymaxX®Antibody Manufacturing Programme for LIV 1205 for Cancer
  • 17 Jul 2016 Anti-cancer monoclonal antibodies available for licensing in World as of 17 Jul 2016. http://www.chiome.co.jp/english/
  • 17 Jul 2016 Preclinical trials in Solid tumours in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top